Premium
Long‐term tolerability and efficacy of cabergoline, a new long‐acting dopamine agonist, in Parkinson's disease
Author(s) -
Inzelberg R.,
Nisipeanu P.,
Rabey M. J.,
Korczyn A. D.
Publication year - 1995
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870100512
Subject(s) - cabergoline , tolerability , dopamine , parkinson's disease , dopamine agonist , levodopa , agonist , medicine , anesthesia , psychology , disease , dopaminergic , adverse effect , receptor , hormone , prolactin
Motor fluctuations constitute a severe complication of chronic levodopa therapy. The addition of dopamine agonists may partially alleviate these responses; however, due to the short half‐lefe of these drugs, several daily doses are required. Cabergoline is a new dopamine agonist with a long half‐life and can be given in a single daily dose. Seventeen patients with severe fluctuations were treated with cabergoline, seven of them for >1 year (up to 39 months). The motor status ameliorated and the percentage of “off” hours significantly decreased in the first year and did not increase significantly later during long‐term follow‐up. Cabergoline is a promising treatment for parkinsonian patients with motor fluctuations.